Transforming growth factor-1 (TGF-1) is a powerful stimulus for collagen formation in vitro. To determine the in vivo effects of TGF-1 on liver fibrogenesis, we generated transgenic mice overexpressing a fusion gene [C-reactive protein (CRP)/TGF-1] consisting of the cDNA coding for an activated form of TGF-1 under the control of the regulatory elements of the inducible human CRP gene promoter. Two transgenic lines were generated with liver-specific overexpression of mature TGF-1. After induction of the acute phase response (15 h) with lipopolysaccharide (100 µg ip), plasma TGF-1 levels reached >600 ng/ml in transgenic animals, which is >100 times above normal plasma levels. Basal plasma levels of uninduced transgenic animals were about two to five times above normal. As a consequence of hepatic TGF-1 expression, we could demonstrate marked transient upregulation of procollagen I and procollagen III mRNA in the liver 15 h after the peak of TGF-1 expression. Liver histology after repeated induction of transgene expression showed an activation of hepatic stellate cells in both transgenic lines. The fibrotic process was characterized by perisinusoidal deposition of collagen in a linear pattern. This transgenic mouse model gives in vivo evidence for the important role of TGF-1 in stellate cell activation and liver fibrogenesis. Due to the ability to control the level of TGF-1 expression, this model allows the study of the regulation and kinetics of collagen synthesis and fibrolysis as well as the degree of reversibility of liver fibrosis. The CRP/TGF-1 transgenic mouse model may finally serve as a model for the testing of antifibrogenic agents.

transforming growth factor-1; stellate cell activation; collagen I; C-reactive protein promoter

This article has been cited by other articles:

				H. Shen, G. Huang, M. Hadi, P. Choy, M. Zhang, G. Y. Minuk, Y. Chen, and Y. Gong Transforming growth factor-{beta}1 downregulation of Smad1 gene expression in rat hepatic stellate cells Am J Physiol Gastrointest Liver Physiol, August 8, 2003; 285(3): G539 - G546. [Abstract] [Full Text] [PDF]

				C. Schramm, M. Protschka, H. H. Kohler, J. Podlech, M. J. Reddehase, P. Schirmacher, P. R. Galle, A. W. Lohse, and M. Blessing Impairment of TGF-beta signaling in T cells increases susceptibility to experimental autoimmune hepatitis in mice Am J Physiol Gastrointest Liver Physiol, March 1, 2003; 284(3): G525 - G535. [Abstract] [Full Text] [PDF]

				P. D. Arkwright, V. Pravica, P. J. Geraghty, M. Super, A. K. Webb, M. Schwarz, and I. V. Hutchinson End-Organ Dysfunction in Cystic Fibrosis: Association with Angiotensin I Converting Enzyme and Cytokine Gene Polymorphisms Am. J. Respir. Crit. Care Med., February 1, 2003; 167(3): 384 - 389. [Abstract] [Full Text] [PDF]

				E. Lutgens, M. Gijbels, M. Smook, P. Heeringa, P. Gotwals, V. E. Koteliansky, and M. J.A.P. Daemen Transforming Growth Factor-{beta} Mediates Balance Between Inflammation and Fibrosis During Plaque Progression Arterioscler. Thromb. Vasc. Biol., June 1, 2002; 22(6): 975 - 982. [Abstract] [Full Text] [PDF]

				M. Weinstein, S. P. S. Monga, Y. Liu, S. G. Brodie, Y. Tang, C. Li, L. Mishra, and C.-X. Deng Smad Proteins and Hepatocyte Growth Factor Control Parallel Regulatory Pathways That Converge on {beta}1-Integrin To Promote Normal Liver Development Mol. Cell. Biol., August 1, 2001; 21(15): 5122 - 5131. [Abstract] [Full Text] [PDF]

				P. D Arkwright, S. Laurie, M. Super, V. Pravica, M. J Schwarz, A K. Webb, and I. V Hutchinson TGF-beta 1 genotype and accelerated decline in lung function of patients with cystic fibrosis Thorax, June 1, 2000; 55(6): 459 - 462. [Abstract] [Full Text]

				L. G. Boros, J. S. Torday, S. Lim, S. Bassilian, M. Cascante, and W.-N. P. Lee Transforming Growth Factor {beta}2 Promotes Glucose Carbon Incorporation into Nucleic Acid Ribose through the Nonoxidative Pentose Cycle in Lung Epithelial Carcinoma Cells Cancer Res., March 1, 2000; 60(5): 1183 - 1185. [Abstract] [Full Text]